164 related articles for article (PubMed ID: 19213570)
1. Anti-angiogenic activity of a novel class of chemopreventive compounds: oleanic acid terpenoids.
Sogno I; Vannini N; Lorusso G; Cammarota R; Noonan DM; Generoso L; Sporn MB; Albini A
Recent Results Cancer Res; 2009; 181():209-12. PubMed ID: 19213570
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis and cancer prevention: a vision.
Noonan DM; Benelli R; Albini A
Recent Results Cancer Res; 2007; 174():219-24. PubMed ID: 17302199
[TBL] [Abstract][Full Text] [Related]
3. The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent.
Vannini N; Lorusso G; Cammarota R; Barberis M; Noonan DM; Sporn MB; Albini A
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3139-46. PubMed ID: 18065492
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent.
Lorusso G; Vannini N; Sogno I; Generoso L; Garbisa S; Noonan DM; Albini A
Eur J Cancer; 2009 May; 45(8):1474-84. PubMed ID: 19223175
[TBL] [Abstract][Full Text] [Related]
5. Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents.
Tosetti F; Ferrari N; De Flora S; Albini A
FASEB J; 2002 Jan; 16(1):2-14. PubMed ID: 11772931
[TBL] [Abstract][Full Text] [Related]
6. Lipoxins exert antiangiogenic and anti-inflammatory effects on Kaposi's sarcoma cells.
Marginean A; Sharma-Walia N
Transl Res; 2015 Aug; 166(2):111-33. PubMed ID: 25814167
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives.
Bisacchi D; Benelli R; Vanzetto C; Ferrari N; Tosetti F; Albini A
Cancer Detect Prev; 2003; 27(3):229-38. PubMed ID: 12787731
[TBL] [Abstract][Full Text] [Related]
8. CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells.
Deeb D; Gao X; Dulchavsky SA; Gautam SC
J Exp Ther Oncol; 2008; 7(1):31-9. PubMed ID: 18472640
[TBL] [Abstract][Full Text] [Related]
9. Broad targeting of angiogenesis for cancer prevention and therapy.
Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD
Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295
[TBL] [Abstract][Full Text] [Related]
10. Anti-angiogenic activity and mechanism of kaurane diterpenoids from Wedelia chinensis.
Huang W; Liang Y; Wang J; Li G; Wang G; Li Y; Chung HY
Phytomedicine; 2016 Mar; 23(3):283-92. PubMed ID: 26969382
[TBL] [Abstract][Full Text] [Related]
11. Anti-angiogenic properties of chemopreventive drugs: fenretinide as a prototype.
Sogno I; Venè R; Sapienza C; Ferrari N; Tosetti F; Albini A
Recent Results Cancer Res; 2009; 181():71-6. PubMed ID: 19213559
[TBL] [Abstract][Full Text] [Related]
12. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
Kerbel RS; Viloria-Petit A; Klement G; Rak J
Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic Potential of Microbial Metabolite Elaiophylin for Targeting Tumor Angiogenesis.
Lim HN; Jang JP; Han JM; Jang JH; Ahn JS; Jung HJ
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498688
[TBL] [Abstract][Full Text] [Related]
14. A natural anti-inflammatory enone fatty acid inhibits angiogenesis by attenuating nuclear factor-κB signaling in vascular endothelial cells.
Furuno A; Watari K; Nakamura M; Fukunaga Y; Jung JH; Ono M
Int J Oncol; 2011 Feb; 38(2):493-501. PubMed ID: 21132269
[TBL] [Abstract][Full Text] [Related]
15. Uncovering the anti-angiogenic effect of semisynthetic triterpenoid CDDO-Im on HUVECs by an integrated network pharmacology approach.
Markov AV; Odarenko KV; Ilyina AA; Zenkova MA
Comput Biol Med; 2022 Feb; 141():105034. PubMed ID: 34802714
[TBL] [Abstract][Full Text] [Related]
16. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology.
van Kempen LC; Leenders WP
Eur J Cell Biol; 2006 Feb; 85(2):61-8. PubMed ID: 16439306
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathways for cancer angioprevention.
Albini A; Noonan DM; Ferrari N
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4320-5. PubMed ID: 17671111
[TBL] [Abstract][Full Text] [Related]
18. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
Fan Y; Peng A; He S; Shao X; Nie C; Chen L
J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
[TBL] [Abstract][Full Text] [Related]
19. OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-κB and MAPK signaling pathways.
Omar HA; Arafa el-SA; Salama SA; Arab HH; Wu CH; Weng JR
Toxicol Appl Pharmacol; 2013 Nov; 272(3):616-24. PubMed ID: 23921148
[TBL] [Abstract][Full Text] [Related]
20. Hop derived flavonoid xanthohumol inhibits endothelial cell functions via AMPK activation.
Gallo C; Dallaglio K; Bassani B; Rossi T; Rossello A; Noonan DM; D'Uva G; Bruno A; Albini A
Oncotarget; 2016 Sep; 7(37):59917-59931. PubMed ID: 27494895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
